Please login to the form below

Not currently logged in
Email:
Password:

EMEA becomes EMA

The European Medicines Agency has officially launched a new organisational structure and visual identity, and will be known as the EMA from now on

The European Medicines Agency has officially launched a new organisational structure and visual identity, and will be known as the EMA from now on.

A key change to the structure is the integration of human pre- and post-authorisation activities into one unit, with the aim of guaranteeing a seamless lifecycle management of medicines. The creation of a new unit for patient health protection further strengthens the Agency's focus on safety monitoring of medicines. In addition, a dedicated group for the management of product data and documentation will improve the efficiency of data management processes throughout the Agency.

This is only the second major reorganisation of the Agency's services since it was established in 1995, and results from the expansion of the Agency's responsibilities and tasks, giving it a stronger role in the protection of public and animal health in Europe.

The number of medicines the Agency oversees has increased, as has the complexity of procedures. All of this has been underpinned by the creation of additional scientific committees and advisory groups, which require enhanced co-ordination and support. Legislative proposals currently being considered by the European Parliament and Council are expected to bring further responsibilities to the Agency.

Welcoming the changes, the Agency's executive director, Thomas Lönngren, said: "This package of changes aims at preparing the Agency for the future. The new structure reinforces our operational ability to deliver on our increasingly complex tasks, and our new visual identity will help to improve the quality and consistency of our communications with our partners and the public."

The new visual identity will help to promote public recognition of the Agency and its contribution to public and animal health.

The Agency's new public website is nearing the end of development and will be launched in the next few months. It will offer improved navigation and search functions. The Agency's website has changed to: www.ema.europa.eu

14th December 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics